ArticleInternational medical case reports journal2025
Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN. Case Presentation: We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN. Conclusion: Upadacitinib may be a safe and potent alternative for patients with refractory PN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.